Denosumab Market Growth Fueled By Rising Osteoporosis Prevalence: A Key Driver Powering Denosumab Market Growth In 2025

The Denosumab Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Denosumab Market Size and Its Estimated Growth Rate?
The market size of denosumab has seen a fast-paced expansion in the past few years. It is projected to surge from $3.27 billion in 2024, escalating to $3.7 billion in 2025, marking a compound annual growth rate (CAGR) of 13.1%. The robust growth in the historical phase is a result of progress in clinical trials and research, FDA authorizations and regulatory accomplishments, increasing cognizance about bone health, along with strategic collaborations and marketing drives.

In the coming years, the denosumab market is anticipated to experience swift expansion. Its size is predicted to reach $5.59 billion in 2029 with a compound annual growth rate (CAGR) of 10.9%. The expected growth in this period can be credited to factors such as the increasing cases of bone metastases, osteoporosis prevalence, development in cancer treatments, heightened awareness of osteoporosis, and regulatory consents for new indications. The forecast period is also likely to witness major trends like the formation of strategic alliances and partnerships, the incorporation of digital health solutions, the extension of indications and clinical applications, and progress in the development of biosimilars.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13835

How Are Emerging Segments Shaping the Denosumab Market Landscape?
The denosumab market covered in this report is segmented -

1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

Which Growth Factors Are Influencing Denosumab Market Expansion?
The rise in osteoporosis cases is anticipated to spur the denosumab market's expansion. Osteoporosis, a condition characterized by weakened bones leading to decreased bone density and an increased chance of fractures, is treated with denosumab. This drug works by preventing bone resorption through its interaction with the RANK ligand. For example, data from the Canadian Longitudinal Study on Aging, published by the US's National Center for Biotechnology Information in September 2023, revealed that the rate of physician-diagnosed osteoporosis stood at 12.7%, and DXA-confirmed osteoporosis was at 5.9% among older adults living at home. Furthermore, a cross-sectional study by Buttros and their team showed a 24.6% osteoporosis prevalence among postmenopausal women aged between 40 and 75, as determined through bone mineral density (BMD) measurements. As a result, the growing cases of osteoporosis are contributing positively to the development of the denosumab market.

Who Are the Dominant Players Across Different Denosumab Market Segments?
Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

What Are the Latest Developing Trends in the Denosumab Market?
Prominent businesses in the denosumab market are strategically focusing on the development of innovative solutions such as frontline treatments for osteoporosis to establish a dominant position in the market. Frontline treatment for osteoporosis is the primary treatment method suggested by medical professionals for individuals diagnosed with osteoporosis. For example, Boan Biotech, a biotechnology firm based in China, got the green light from China's National Medical Products Administration (NMPA) in November 2022 for its denosumab biosimilar, Boyoubei. This achievement qualifies it as the first Chinese firm to produce a denosumab injection. Besides China, the drug is also being developed for international markets, including Europe and the United States, with a view to global distribution. Boyoubei has been suggested as a frontline treatment for osteoporosis in several treatment regimens. The drug holds enormous potential to significantly decrease the risk of hip, non-vertebral, and vertebral fractures among patients. Furthermore, Boyoubei marks itself as the world's first biosimilar to Prolia (the original denosumab) to gain marketing approval.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Which Geographic Regions Are Expected to Dominate the Denosumab Market in the Coming Years?
North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Denosumab Market?
2. What is the CAGR expected in the Denosumab Market?
3. What Are the Key Innovations Transforming the Denosumab Industry?
4. Which Region Is Leading the Denosumab Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.